Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Short-term Investments (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Short-term Investments for 12 consecutive years, with $9.2 million as the latest value for Q1 2026.

  • For Q1 2026, Short-term Investments rose 122.91% year-over-year to $9.2 million; the TTM value through Mar 2026 reached $9.2 million, up 122.91%, while the annual FY2025 figure was $19.6 million, 95.59% up from the prior year.
  • Short-term Investments hit $9.2 million in Q1 2026 for Syndax Pharmaceuticals, down from $19.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $346.6 million in Q2 2025 and bottomed at $115000.0 in Q4 2022.
  • Average Short-term Investments over 5 years is $108.0 million, with a median of $16.8 million recorded in 2024.
  • On a YoY basis, Short-term Investments climbed as much as 239294.78% in 2023 and fell as far as 97.22% in 2023.
  • Syndax Pharmaceuticals' Short-term Investments stood at $115000.0 in 2022, then soared by 239294.78% to $275.3 million in 2023, then tumbled by 96.36% to $10.0 million in 2024, then skyrocketed by 95.59% to $19.6 million in 2025, then plummeted by 53.23% to $9.2 million in 2026.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $9.2 million, $19.6 million, and $18.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.